Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer

被引：0
|
作者：
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
机构：
[1] KU Leuven Univ Leuven, Leuven, Belgium
[2] KU Leuven Univ Leuven, Lab Translat Cell & Tissue Res, Leuven, Belgium
[3] Univ Leuven, Dept Pathol, Leuven, Belgium
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD3-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-09
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HER2 TUMOR HETEROGENEITY AND DISCREPANCIES IN HER2 STATUS BETWEEN PRIMARY TUMOR AND CORRESPONDING CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER PATIENTS
    Migliaccio, I.
    Galardi, F.
    Bessi, S.
    Capaccioli, G.
    Biagioni, C.
    Truglia, M.
    Santarpia, L.
    Giannini, A.
    Di Leo, A.
    Pestrin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 25 - 25
  • [22] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Telli, Melinda L.
    Kimmick, Gretchen
    Winer, Eric
    Naughton, Michael
    Goetz, Matthew P.
    Russell, Christy
    Tripathy, Debu
    Cobleigh, Melody
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey
    Niravath, Polly Ann
    Thomas, Shana
    Anderson, Jill
    Bumb, Caroline
    Banks, Kimberly C.
    Lanman, Richard B.
    Bryce, Richard
    Lalani, Alshad S.
    Pfeifer, John
    Hayes, Daniel F.
    Pegram, Mark
    Blackwell, Kimberly
    Bedard, Philippe L.
    Al-Kateb, Hussam
    Ellis, Matthew J. C.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5687 - 5695
  • [23] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [24] Dual HER2 inhibition and paclitaxel in metastatic breast cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2015, 16 (02): : E57 - E57
  • [25] Precision medicine for HER2 negative metastatic breast cancer
    Hara, Fumikata
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
  • [27] Dual HER2 Blockade Slows Metastatic Breast Cancer
    Bender, Eric
    CANCER DISCOVERY, 2012, 2 (01)
  • [28] Major Strides in HER2 Blockade for Metastatic Breast Cancer
    Sharma, Priyanka
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 669 - 671
  • [29] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
  • [30] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
12345